bi 907828

Small moleculeexperimental

Clinical trial activity

11 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
5
Phase 3
3
Phase 4
0

Earliest trial started May 21, 2018 (NCT03449381)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1c(C(=O)O)ccc2c3n(nc12)[C@@H]1[C@H](C3)N(CC2CC2)[C@@]2(C(=O)Nc3cc(Cl)ccc32)[C@H]1c1cccc(Cl)c1F
Mol. weight
591.47 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06619509Phase 2Dec 4, 2024Boehringer Ingelheim
NCT06370871Phase 3Jun 27, 2024Boehringer Ingelheim
NCT06084689Phase 2Jan 1, 2024Boehringer Ingelheim, Institut Bergonié
NCT06058793Phase 3Dec 12, 2023Boehringer Ingelheim
NCT05512377Phase 2Nov 25, 2022Boehringer Ingelheim
NCT05613036Phase 1Nov 8, 2022Boehringer Ingelheim
NCT05376800Phase 1Jul 28, 2022Boehringer Ingelheim
NCT05372367Phase 1Jun 30, 2022Boehringer Ingelheim
NCT05218499Phase 2/Phase 3 (Phase 3)Mar 25, 2022Boehringer Ingelheim
NCT03964233Phase 1Jun 11, 2019Boehringer Ingelheim
NCT03449381Phase 1May 21, 2018Boehringer Ingelheim
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit111032018
Institut BergoniéAcademic/Hospital1112024
2 organizations
Page 1 / 1